Pinned Tweet
🎙️ ConferenceHype turns major medical conferences & journals into AI-narrated video updates. YouTube and X for now.
🔔 Subscribe on YouTube
❤️ Like & follow here
💡 Got a conference, journal, or story idea? Reply or tag #ConferenceHype — we read
conferencehype.com
1
146
CTAD 2026 Update 6: #CTAD26 @CTADconference @biogen @ionispharma CELIA extension: diranersen 60 mg slowed CDR-SB decline 38% at week 96 vs original placebo (1.09 points), up from 26% at 18 months. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=xha5iTZ-…
1
4
396
CTAD 2026 Update 5: #CTAD26 @CTADconference Oral PRI-002, PRImus-AD Phase 2, 304 patients: missed week 48 CDR-SB goal; exploratory week 72 ADAS-Cog13 slowing 35.9% per protocol (p=0.022). To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=FB_Qr0Ss…
1
92
CTAD 2026 Update 5: #CTAD26 @CTADconference @AcadiaPharma Phase 2 RADIANT, remlifanserin for Alzheimer's psychosis: 44.0% vs 31.8% improved at week 6 (nominal); primary goal narrowly missed. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=FB_Qr0Ss…
48
SfN 2026 Update 3: #SfN26 @SfNtweets AAV2-NGF gene therapy for early Alzheimer's: gene still active 15 years on, no toxicity in 10 brains; Phase 2 did not slow decline. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=CK5ZX2Z7…
60
SfN 2026 Update 3: #SfN26 @SfNtweets Open-label Phase 2, NouvNeu001 cells in advanced Parkinson's: off-medication motor score 58.47 to 41.65 at 6 months (n=17). To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=CK5ZX2Z7…
51
SfN 2026 Update 3: #SfN26 @SfNtweets @NervgenP Phase 1b/2a, 20 people with chronic spinal cord injury: NVG-291 raised hand-muscle motor responses 9.43% of max at week 12 (p=0.0155). To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=CK5ZX2Z7…
117
ObesityWeek 2026 Update 11: #OW2026 @ObesityWeek @Veru_Pharma QUALITY post hoc, ages 65+: enobosarm plus semaglutide raised stair-climb power 16.48% vs semaglutide alone at 16 weeks. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=63Krf8Dk…
2
28
ObesityWeek 2026 Update 11: #OW2026 @ObesitySociety @RhythmPharma 2-year TRANSCEND extension, setmelanotide in acquired hypothalamic obesity: BMI -18.8% continuous, -16.5% after placebo switch. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=63Krf8Dk…
2
35
CTAD 2026 Update 4: #CTAD26 @CTADconference @biogen Five-year Clarity AD: lecanemab 2.05 points better on CDR-SB vs external ADNI cohort; 36% lower next-stage risk. No placebo after 18 months. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=nnXzfdCt…
3
123
CTAD 2026 Update 4: #CTAD26 @CTADconference Polaris-AD news reports: oral AR1001 31% slower CDR-SB worsening in monotherapy group; full population missed. Hope: Spectris missed primary. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=nnXzfdCt…
3
257
ObesityWeek 2026 Update 10: #ObesityWeek @ObesityWeek LEAP phentermine: about 6% weight loss at 2 years, BP did not rise (no placebo figures yet). If you like this content please hit the follow button. Like and retweet, then like and subscribe on YouTube: youtube.com/watch?v=RUDWk8-b…
2
19
ObesityWeek 2026 Update 10: #ObesityWeek @novonordisk STEP Young: 79% vs 23% of children dropped a BMI category at week 68 (NEJM). If you like this content please hit the follow button. Like and retweet, then like and subscribe on YouTube: youtube.com/watch?v=RUDWk8-b…
2
22
ObesityWeek 2026 Update 10: #ObesityWeek #OW2026 @ObesitySociety @novonordiskus STEP Young, kids 6-<12: BMI -13.5% vs +2.7% on placebo at week 68. If you like this content please hit the follow button. Like and retweet, then like and subscribe on YouTube: youtube.com/watch?v=RUDWk8-b…
2
19
ISA 2026 Preview 1: #ISA2026 @AstraZeneca CARES anselamimab missed overall (p=0.332); kappa subgroup HR 0.38 for death, nominal p. If you like this content please hit the follow button. Like and retweet, then like and subscribe on YouTube: youtube.com/watch?v=wglDHe8S…
2
26
ISA 2026 Preview 1: #ISA2026 @AstraZeneca @ionispharma Eplontersen CARDIO-TTRansform missed its primary endpoint: rate ratio 0.89, p=0.277. If you like this content please hit the follow button. Like and retweet, then like and subscribe on YouTube: youtube.com/watch?v=wglDHe8S…
2
39
ISA 2026 Preview 1: #ISA2026 @Alnylam Vutrisiran HELIOS-B: 28% lower risk of death or recurrent CV events (HR 0.718); neuropathy poster Monday. If you like this content please hit the follow button. Like and retweet, then like and subscribe on YouTube: youtube.com/watch?v=wglDHe8S…
1
32
ISA 2026 Preview 1: #ISA2026 @ISA_Amyloidosis @BridgeBioPharma Acoramidis ATTRibute-CM: win ratio 1.8 vs placebo (p<0.001); 28 abstracts at ISA. If you like this content please hit the follow button. Like and retweet, then like and subscribe on YouTube: youtube.com/watch?v=wglDHe8S…
ObesityWeek 2026 Update 9: #ObesityWeek @omadahealth GLP-1 Care Track: 12-month persistence 58% semaglutide, 75% tirzepatide (observational). If you like this content please hit the follow button. Like and retweet, then like and subscribe on YouTube: youtube.com/watch?v=Kg3rtzSC…
2
21
ObesityWeek 2026 Update 9: @ObesityWeek VK2735 Venture: 74% moved down at least one BMI category at 13 weeks vs 15% on placebo (exploratory). If you like this content please hit the follow button. Like and retweet, then like and subscribe on YouTube: youtube.com/watch?v=Kg3rtzSC…
2
23
ObesityWeek 2026 Update 9: #ObesityWeek @ObesitySociety @novonordiskus CagriSema early responders lost 25.4% at week 68 vs 17.8% (post hoc). If you like this content please hit the follow button. Like and retweet, then like and subscribe on YouTube: youtube.com/watch?v=Kg3rtzSC…
2
23
